Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects (Oberab).

Trial Profile

Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects (Oberab).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Rabeprazole (Primary) ; Omeprazole
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacodynamics
  • Acronyms OBERAB
  • Most Recent Events

    • 10 May 2011 Results presented at Digestive Disease Week 2011.
    • 23 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top